Clinical Trial Update: Tolerability Study of Xerecept® in Pediatric Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 tolerability study of Xerecept in pediatric patients with brain edema or brain tumors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Edema
• Brain Tumor

Drugs mentioned

• XERECEPT (human corticotropin-releasing factor)

Snippet

Sponsor: Celtic Pharma Development Services | Conditions: Brain Edema, Brain Tumor | Phase 1, Phase 2 | Status: TERMINATED